Accuray ARAY
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Accuray (ARAY)
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Key Insights
Critical company metrics and information
Latest Closing Price
$1.86Market Cap
$191.26 MillionPrice-Earnings Ratio
-46.50Total Outstanding Shares
102.83 Million SharesTotal Employees
987Dividend
No dividendIPO Date
February 8, 2007SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
NASDAQType
Common StockHeadquarters
1240 deming way, Madison, WI, 53717Homepage
https://www.accuray.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-3.71 Million |
| Net Cash Flow From Financing Activities | $1.40 Million |
| Net Cash Flow | $-9.10 Million |
| Net Cash Flow From Investing Activities | $-3.95 Million |
| Net Cash Flow From Operating Activities | $-3.71 Million |
| Net Cash Flow From Investing Activities, Continuing | $-3.95 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Available To Common Stockholders, Basic | $-4.37 Million |
| Benefits Costs and Expenses | $455.28 Million |
| Other Operating Expenses | $92.88 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Income Tax Expense/Benefit, Deferred | $599,000 |
| Basic Earnings Per Share | $-0.04 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-10.83 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-12.57 Million |
| Other Comprehensive Income/Loss | $-12.00 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Assets | $478.38 Million |
| Other Non-current Liabilities | $53.52 Million |
| Other Non-current Assets | $125.61 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Inventory | $148.83 Million |
| Accounts Receivable | $87.28 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ARAY from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.